AstraZeneca, US ink $486M deal for COVID-19 antibody drug

AstraZenecas treatment, called AZD7442, consists of a mix of antibody drugs, using a formula comparable to Regenerons antibody mixed drink that was just recently provided to President Donald Trump. Both Regeneron and Eli Lilly have actually looked for emergency situation approval from the FDA for their antibody treatments.

HHS will pay pharma huge AstraZeneca $486 million to secure as numerous as 100,000 doses of its experimental COVID-19 antibody drug, along with support scientific trials for the treatment.

More articles on drug store:7 essential uncertainties surrounding the COVID-19 vaccine raceMallinckrodt apply for Chapter 11 bankruptcyOperation Warp Speed czar: Vaccine approval most likely to be looked for around Thanksgiving


The department revealed the deal Oct. 9 as part of Operation Warp Speed, the White Houses task force to quickly establish COVID-19 vaccines and treatments.

Katie Adams –
Monday, October 12th, 2020

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

” This contract with the U.S. federal government will assist speed up the advancement of our long-acting antibody combination which has the potential to provide lasting and immediate result in both avoiding and dealing with COVID-19 infections,” AstraZeneca CEO Pascal Soriot said in a news release. “We will be assessing the LAAB combination in various settings from prophylaxis, to outpatient treatment to hospitalization, with a focus on helping the most vulnerable people.”.